showed that IL-32 may have a contradictory role in the TME of ESCC, which enhanced the anti-tumor activity by promoting IFN-γ expression in CD8+ T cells, while suppressing the immune responses by inducing Foxp3 expression in CD4+ T cells (85). The gene discussed is CD8A; the disease is neoplasm.